Cabaletta Bio Inc expected to post a loss of 65 cents a share - Earnings Preview
Cabaletta Bio Inc
CABA is expected to show a rise in quarterly revenue when it reports results on August 6 (estimated) for the period ending June 30 2025The Philadelphia Pennsylvania-based company is expected to report revenue of $4.167 million, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for Cabaletta Bio Inc is for a loss of 65 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Cabaletta Bio Inc is $15.00, about 90.4% above its last closing price of $1.44
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.64 | -0.64 | -0.71 | Missed | -10.4 |
Dec. 31 2025 | -0.63 | -0.65 | Missed | -3 | |
Sep. 30 2024 | -0.59 | -0.60 | -0.62 | Missed | -4 |
Jun. 30 2024 | -0.56 | -0.55 | -0.56 | Missed | -2.2 |
Mar. 31 2024 | -0.47 | -0.48 | -0.51 | Missed | -7.2 |
Dec. 31 2023 | -0.40 | -0.39 | -0.46 | Missed | -17.2 |
Sep. 30 2023 | -0.41 | -0.40 | -0.37 | Beat | 8.3 |
Jun. 30 2023 | -0.44 | -0.44 | -0.37 | Beat | 16.4 |
This summary was machine generated August 4 at 14:11 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
